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Strengths and limitations of this study
 ► A large human papillomavirusHPV vaccination tri-
al cohort with standardised clinical and laboratory 
procedures.
 ► The repeated self-reported study questionnaires 
were comprehensive and less subject to recall bias.
 ► Use of the overall cervical atypia endpoint increases 
study power but may have diluted the effects.
AbStrACt
Objective We investigated whether the risk of cervical 
atypia is associated with a short interval between the age 
at first sexual intercourse (FSI) or age at the start of oral 
contraceptive (OC) use and menarche.
Design A population-based cohort study.
Setting Finnish women in the age range of 16–17 
years old were enrolled in the PATRICIA trial of human 
papillomavirus (HPV) 16/18 vaccine efficacy.
Participants The association of cervical atypia 
with the interval between FSI or start of OC use and 
menarche was assessed in the control arm (hepatitis 
A vaccinated) who had participated in biannual clinical 
follow-up visits for 4 years. Altogether, 913 women 
had normal baseline cervical cytology and answered 
behavioural questionnaires at enrolment and end of 
the follow-up.
Main outcome measure ORs with 95% CIs using 
univariate and multivariable logistic regression were 
used to assess the association between cervical 
atypia and the interval between FSI or the start of OC 
use and menarche.
results The mean ages at menarche, FSI and the start of 
OC use were 12.4, 16.0 and 16.4. Chlamydia trachomatis 
infection was associated with an increased risk of cervical 
atypia in women with a short (<3 years) interval between 
menarche and FSI/start of OC use (OR 1.8, 95% CI 1.0 to 
3.6 and OR 2.2, 95% CI 1.0 to 5.1). Whereas HPV 16/18 
infection was associated with increased atypia risk 
estimates in women with a longer (≥3 years) interval (OR 
1.8, 95% CI 1.1 to 2.7 and OR 1.4, 95% CI 1.0 to 2.1). In 
women with a short interval between menarche and FSI, 
early age at the start of OC use was not associated with an 
increased risk of cervical atypia in the univariate (OR 0.7) 
nor multivariable analyses.
Conclusion Short interval between menarche and the age 
at start of sexual activity does not increase the risk of HPV-
associated cervical atypia.
trial registration number NCT00122681.
IntrODuCtIOn
Sexually transmitted human papillo-
mavirus (HPV) infections cause both 
cytological and histological cervical abnor-
malities.1 2 Clinical manifestations of 
persistent infection with oncogenic HPV 
types and squamous intraepithelial lesions 
(SILs) of the cervix, also known as cervical 
intraepithelial neoplasia (CIN), are the 
precursors of invasive cervical cancer 
(ICC).3–5 In addition to HPV, other risk 
factors which may play a role in the patho-
genesis of ICC are smoking,6 Chlamydia 
trachomatis,7 lifetime number of sexual 
partners (LNSPs),8 age at first sexual inter-
course (FSI),9 parity10 and the use of oral 
contraceptives (OCs).11
Both early age at FSI and early age at 
the start of OC use are associated with an 
increased risk of SIL and CIN.9 12–14 Further-
more, a short lag between menarche and FSI 
is a risk factor of SIL/CIN.9 12 14 This is prob-
ably due to exposure of immature cervical 
cells to infection with HPV, as persistent 
infections with oncogenic HPV types are 
established more readily in an immature 
cervix.13 15 However, whether or not early start 
of OC use has an independent role here is 
unknown. The interplay of the time interval 
between age at the start of OC use or FSI and 
menarche in cervical carcinogenesis has not 
been studied.
In a large cohort study, we have investi-
gated whether the risk of cervical atypia is 
associated with a short interval between 
menarche and the age at the start of OC use 
or FSI.
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Table 1 Characteristics of 22-year-old women (n=913) who 
attended eight biannual follow-up visits and a subgroup of 
these women (n=197) who developed cervical atypia during 
4 years of follow-up
Characteristics
Attendees Women with atypia
n=913 % n=197 %
Age
  22 422 46.2 94 47.7
  23 489 53.6 103 52.3
  24 2 0.2 0 0
  Missing 0 0 0 0
Age at menarche
  ≤11 194 21.3 52 26.4
  12–14 659 72.2 136 69.0
  ≥15 52 5.7 6 3.10
  Missing 8 0.8 3 1.5
Age at FSI
  12–16 602 65.9 129 65.5
  17–22 273 29.9 60 30.5
  Missing 38 4.2 8 4.0
LNSPs
  0 3 0.3 1 0.5
  1 131 14.3 29 14.7
  2–4 283 31.0 57 28.9
  5–9 236 25.9 50 25.4
  ≥10 230 25.2 55 28.0
  Missing 30 3.3 5 2.5
OC use
  Non-user 62 6.8 15 7.6
  User 842 92.2 179 90.9
  Missing 9 1.0 3 1.5
Age at start of OC use
  12–16 504 55.2 104 52.8
  17–22 371 40.6 85 43.1
  Missing 38 4.2 8 4.1
Condom use
  Non-user 414 45.4 97 49.2
  User 406 44.5 83 42.1
  Don't know 76 8.3 16 8.1
  Missing 17 1.8 1 0.5
Smoking
  Never 525 57.5 108 54.8
  Past 93 10.2 16 8.1
  Present 291 31.9 73 37.1
  Missing 4 0.4 0 0
HPV 16
  Negative 711 77.9 145 73.6
  Positive 201 22.0 52 26.4
Continued
Characteristics
Attendees Women with atypia
n=913 % n=197 %
HPV 18
  Negative 792 86.8 165 83.8
  Positive 120 13.1 32 16.2
Chlamydia
  Negative 811 88.8 175 88.8
  Positive 102 11.2 22 11.2
FSI, first sexual intercourse; HPV, human papillomavirus; 
LNSPs, lifetime number of sexual partners; OC, oral 
contraceptive.
Table 1 Continued
MAterIAlS AnD MethODS
Study sample
The study population consists of women enrolled in 
the control arm of a double-blinded, multi-national 
randomised control PATRICIA trial whose primary aim 
was to evaluate the vaccine efficacy of the HPV 16/18 
vaccine against CIN2+.16 17 Full description of the trial, 
details of recruitment and final results on its endpoints 
have been reported earlier.18 PATRICIA enrolled only 
16–17-year-old women in Finland (2409 received at 
least one dose of HPV 16/18 vaccine) and 2399 women 
(received at least one dose of hepatitis A virus (HAV) 
vaccine). The criteria of having no more than six LNSPs 
was not applied in Finland, so all women interested and 
willing to participate in the study were included.18 Written 
informed consent was obtained from all the participants.
The present study began after the end of the clinical 
PATRICIA trial. All 4808 women who were approximately 
22 years old when exiting the trial were sent a question-
naire on living conditions, lifestyle habits and sexual 
health. All the women (913) who had received the HAV 
vaccine, answered the questionnaires both at enrolment 
and at the end of the follow-up, and had negative cytology 
at baseline and before menarche were eligible (table 1). 
Cytology outcomes were detected at the follow-up visits.
Data collection
In addition to collecting information on living conditions 
and lifehabits, the questionnaires collected information 
about history of OC use, use of other contraceptives, 
smoking, menarche and sexual habits. The end of study 
questionnaire was more complete regarding the initi-
ation of sexual habits, and was therefore used in the 
analysis. The age at the start of OC use, menarche and 
age at FSI were the independent variables in this study. 
Intervals of <3 years, or more than or equal to 3 years 
were calculated between menarche and the age at the 
start of OC use, as well as between menarche and FSI. 
Data on smoking (‘never smokers’, ‘past smokers’ and 
‘present smokers’), LNSPs (‘none’, ‘1’, ‘2–4’, ‘5–9’ and 
‘more than 10’), condom use (‘non-user’, ‘user’ and ‘do 
not know’) and sexually transmitted infections (HPV 
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Table 2 Distribution of cervical atypia risk factors by interval between menarche and age at the start of OC use or age at the 
FSI in young adult women followed up for 4 years
Category
Interval between menarche and age at the 
start of OC use Interval between menarche and the FSI
Interval <3 years Interval ≥3 years Interval <3 years Interval ≥3 years
(n=192) (n=675) (n=302) (n=566)
n/Mean (%/SD) n/Mean (%/SD) n/Mean (%/SD) n/Mean (%/SD)
Chlamydia trachomatis 39 (20.3) 59 (8.7) 54 (18.0) 44 (7.8)
HPV 16 55 (28.7) 142 (21.1) 97 (32.2) 100 (17.8)
HPV 18 35 (18.2) 83 (12.3) 47 (15.6) 71 (12.5)
HPV 16/18 69 (35.9) 190 (28.2) 115 (38.2) 144 (25.4)
Smoking
  Never 84 (43.8) 405 (60.4) 134 (44.8) 356 (63.0)
  Past smoker 22 (11.4) 69 (10.2) 37 (12.4) 54 (9.6)
  Present smoker 86 (44.8) 197 (29.4) 128 (42.8) 155 (27.4)
Age at menarche 13.4 (1.2) 12.2 (1.1) 13.1 (1.3) 12.1 (1.1)
Age at FSI 14.7 (1.2) 16.3 (1.9) 14.6 (1.2) 16.7 (1.9)
Age at start of OC use 14.9 (1.2) 16.9 (1.7) 15.3 (1.3) 17.1 (1.7)
Lifetime number of partners
  0 0 1 (0.2) 0 1 (0.2)
  1 11 (5.7) 119 (17.6) 14 (4.6) 116 (20.5)
  2–4 46 (24.0) 230 (34.1) 73 (24.2) 204 (36.0)
  5–9 69 (36.0) 163 (24.2) 98 (32.5) 134 (23.7)
  >10 66 (34.4) 162 (24.0) 117 (38.7) 111 (19.6)
FSI, first sexual intercourse; HPV, human papillomavirus; OC, oral contraceptive.
16/18 and C. trachomatis) were used as covariables, as they 
are important factors in cervical carcinogenesis. These 
covariables were used in both the univariate and multi-
variable models to evaluate if the short intervals between 
menarche and FSI or age at the start of OC use are truly 
associated with or modify the risk of cervical atypia.
laboratory analysis and endpoints
In the PATRICIA trial, biannual cervical cytological and 
DNA samples were obtained in conjunction with pelvic 
examination. PCR analyses for C. trachomatis and HPV 
DNA were performed as described.18
At the follow-up visits, the first cytological findings of 
atypical squamous cells of undetermined significance 
(ASCUS), low-grade squamous intraepithelial lesions 
(LSIL) and high-grade squamous intraepithelial lesions 
(HSIL) were registered as index incident cases for the 
statistical analysis. Colposcopy-directed biopsy samples 
were also obtained during the trial. The first histopatho-
logical findings of CIN grades 1, 2 and 3 were also listed as 
the index cases for statistical analysis. SIL and CIN cases 
were combined together to form a new variable, cervical 
atypia.
Cervical atypia findings were registered by the interval 
between menarche and FSI or the start of OC use to form 
four mutually exclusive different individual outcome 
variables; (1) cervical atypia with shorter than 3 years lag 
between menarche and FSI, (2) cervical atypia with equal 
or longer than 3 years lag between menarche and FSI, 
(3) cervical atypia with shorter than 3 years lag between 
menarche and OC use and (4) cervical atypia with equal 
or longer than 3 years lag between menarche and OC 
use.
Patient and public involvement
Patient (adolescent study subjects) and public (parental) 
involvement in the planning and design of the study was 
noted as their attitudes and willingness to participate in 
a HPV vaccination trial in a questionnaire sent to house-
holds (parents and their adolescent daughter) in one 
of the major study site communities.19 No patients with 
cervical cytological atypia were involved in setting the 
research questions, the outcome measures or in devel-
oping the plans for recruitment, design or implementa-
tion of the study.
There are no plans to directly disseminate the results 
of the research to study participants; however, the results 
have and will be disseminated to a wider audience, 
including members of the public, patients, health profes-
sionals and experts through written communication, 
events and conferences, networks and social media.
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Table 4 Relative risk (ORs with 95% CI) of cervical atypia (cytological SIL and/or CIN grade 1 or worse, CIN1+) stratified by 
the interval between menarche and age at FSI or between menarche and the age at start of OC use in young adult women 
followed up for 4 years
Frequency and relative risk of cytological atypia: SIL or CIN1 in the different categories by interval from menarche
Variable
Category 1 Category 2
Menarche to FSI <3 years
SIL/CIN1+
Menarche to start of OCs ≥3 years
SIL/CIN1+
n/N OR (95% CI) n/N OR (95% CI)
Lag between FSI and menarche
  <3 years. 53/301 NA 23/110 0.9 (0.5 to 1.4) 0.9 (0.8 to 1.0)
  ≥3 years NA NA 132/565 1 *Interval (cont.)
Lag between start of OCs and menarche
  <3 years. 30/191 0.7 (0.4 to 1.3) 0.9 (0.9 to 1.0) NA NA
  ≥3 years 23/110 1 *Interval (cont.) 155/675 NA
CIN, cervical intraepithelial neoplasia; FSI, first sexual intercourse; OC, oral contraceptive; SIL, squamous intraepithelial lesion.
Statistical analysis
The outcome variables were analysed in the univariate 
and multivariable logistic regression models along with 
the independent variables and above listed covariates. 
The risks are reported as the ORs with 95% CI. The statis-
tical analysis was performed using Stata V.14.0 (Stata Corp 
LP, Statistical Software: Release 14).
reSultS
Baseline characteristics of our study cohort attending 
biannual follow-up visits for 4 years are materially homo-
geneous with little variation (table 1).
Age at menarche was between 12 and 14 years for 659 
(72.2%) participants. Age at the FSI and age at the start 
of OC use were between 12 and 16 years for 602 (65.9%) 
and 504 (55.2%) participants, respectively. No cervical 
atypia cases were found before the menarche, age at the 
FSI or the age at the start of OC use. One cervical atypia 
case occurring concomitantly with the start of OC use was 
removed from the analyses.
By the end of the follow-up period, out of 913 women, 
156 (17.1%) had ASCUS, 189 (20.7%) had LSIL, 5 (0.6%) 
had HSIL, 40 (4.4%) had CIN1, 22 (2.41%) had CIN2 
and 8 (0.9%) had CIN3. 197 (21.6%) of 913 women were 
identified with cervical atypia (table 1). Almost one-third 
of the women with cervical atypia (55 (28.0%) of 197) had 
more than 10 LNSPs. Half of the women with or without 
cervical atypia, 49.2% and 45.4% respectively, did not 
regularly use condoms. Most of the women (179 (90.9%) 
of 197) with cervical atypia had used OCs. Age at the start 
of OC use for the majority of these women (104 (52.8%) 
of 197) was between 12 and 16 years (table 1). During 
the 4 year follow-up, 201 (22%) of all women were tested 
positive for HPV 16 and 120 (13.1%) were tested posi-
tive for HPV 18 (table 1). One-third of women with either 
HPV 16 or HPV 18, or both were diagnosed with cervical 
atypia during the follow-up. The number of women who 
tested positive for C. trachomatis was 102 (11.2%), and the 
number of C. trachomatis positive women with cervical 
atypia was 22 (11.2%) (table 1).
We categorised the risk factors of cervical atypia 
according to the interval between menarche and age at 
the start of OC use, or between menarche and age at FSI 
using a stratification of <3 years and ≥3 years (table 2).
The mean ages at menarche, at FSI and at the start 
of OC use were similar in the corresponding categories 
(table 2). Women in the <3 years interval categories were 
more often HPV 16 positive than women in the ≥3 years 
interval categories (table 2). The percentages of women 
with multiple (>5) LNSPs were also higher in the short 
interval categories (table 2).
In the univariate analysis, the risk of cervical atypia asso-
ciated with its known risk factors was evaluated separately 
in the short and long interval categories (table 3).
Cervical atypia risk estimates associated with HPV 
16/18 were increased (OR 1.8, 95% CI 1.1 to 2.7 and OR 
1.4, 95% CI 1.0 to 2.1) in the longer (≥3 years) interval 
categories. On the contrary, the cervical atypia risk asso-
ciated with C. trachomatis was increased (OR 1.8, 95% CI 
1.0 to 3.6 and OR 2.2, 95% CI 1.0 to 5.1) in the short (<3 
years) interval categories. Condom use was not associated 
with a significantly decreased risk of cervical atypia in any 
of the interval categories (table 3).
In univariate analyses, the risk of cervical atypia 
associated with the short interval between menarche 
and age at the start of OC use appeared to be some-
what decreased (OR 0.7, 95% CI 0.4 to 1.3) when the 
interval between menarche and age at the FSI was short 
(table 4).
The risk estimate, however, approached unity (OR 0.9) 
when the interval was estimated as a continuous variable. 
There was no risk of atypia associated with the long-
term interval between menarche and the start of OC use 
(table 4).
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In multivariable analyses, stepwise exclusion of one 
variable at a time from the multivariable model was 
performed to check the interdependency of the interval 
between menarche, age at the start of OC use and age at 
FSI in this context. Exclusion of any of the abovemen-
tioned variables did not affect significance of the esti-
mates (data not shown).
DISCuSSIOn
We found that cervical atypia was not associated with early 
start of sexual activity after menarche. The risk of cervical 
atypia associated with C. trachomatis was increased shortly 
after start of sexual activity following menarche, whereas 
the risk of cervical atypia was associated with HPV 16/18 
infections more than 3 years after the start of sexual 
activity following menarche.
Our large HPV-vaccination-trial-derived population 
of young adult women, with uniform ethnicity (97% 
Caucasian Finnish women), and the standardised clin-
ical and laboratory procedures are noteworthy strengths 
of the study. In young Finnish women, HIV infection has 
been and is extremely rare ( www. thl. fi). Furthermore, 
over the entire follow-up period the trial participants 
received regular sexual health counselling which prob-
ably helped in retaining the participants and reduced 
possible confounding and bias in our study. To the best of 
our knowledge, the association between interval between 
menarche and the age at the start of OC use with cervical 
atypia has now been assessed for the first time.
Some limitations of our study are as follows. The use of 
the overall cervical atypia endpoint, which was necessary 
to retain the statistical power of the study strata. The study 
questionnaires used were self-reported at the ages of 18 
and 22 years, the latter of which is subject to recall bias. 
The endpoint questionnaire (at age 22) was, however, in 
line with the enrolment questionnaire (at age 18), for 
example, for menarche. Moreover, questionnaire-based 
information regarding sexual behaviour is supposed 
to have adequate validity and reliability.20 21 It gave the 
most comprehensive information about sexual risk-taking 
characteristics of the study subjects over time. This was 
important when assessing the longitudinal effects of 
OC use on prospective development of cervical atypia 
following the exposures. Free contraceptives were distrib-
uted to the participants during the trial period, which 
might have increased the proportions of OC and condom 
users in our study.
The absence of HPV 16/18 associated risk of cervical 
atypia in women with short lag between menarche and 
the start of sexual activity appears to defy the assumption 
that the immature cervical transformation zone is espe-
cially prone to persistent HPV infection.15 Our observa-
tion is in line with Collins et al, who reported that the 
increased interval between menarche and the age at the 
FSI increases the risk of HPV infection.22 Overall cervical 
atypia, the most common clinical manifestation of genital 
HPV infection, needs some time to develop.
On the other hand, our findings seem to contradict a 
study by Ruiz et al who first reported that short interval 
between menarche and age at the FSI is a predictor of 
cervical cytological abnormalities and CIN.9 While our 
homogeneous study population had ampler power to 
detect a threefold increased risk (see online supplemen-
tary appendix), their study population was heteroge-
neous and had only baseline sexual risk-taking behaviour 
questionnaire data, which could not elaborate (possible 
changes in) the risk-taking behaviour during the 
follow-up. Furthermore, we found a lack of association 
between short interval of menarche and two different 
measures of the start of sexual activity (age at FSI and age 
at the start of OC use). However, these different obser-
vations on the interval between menarche and start of 
sexual activity, and the risk of cervical atypia,9 12–14 may 
also reflect limited sample sizes.
Our group has earlier reported that when C. trachomatis 
infection precedes or cooccurs with HPV infection the 
risk of high-grade cervical neoplasia associated with the 
joint infection is very high.23 Our results on the increased 
risk of C. trachomatis infection with cervical atypia espe-
cially in women with a short lag between menarche and 
the start of sexual activity emphasise the need to identify, 
treat and follow-up adolescent females with C. trachomatis.
In conclusion, while our study does not support the 
hypothesis that a short interval between menarche and 
age at the start of sexual activity always increases the risk 
of cervical atypia, early age of acquiring C. trachomatis 
infections may set the stage for cervical carcinogenesis 
and should be identified and treated.
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